medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


Consecuencias de la reabsorción enteral de lípidos ¿Se justifica el tratamiento combinado estatina-ezetimiba de primera línea?

Córdova AL

Idioma: Español
Referencias bibliográficas: 14
Paginas: 385-389
Archivo PDF: 63.54 Kb.


RESUMEN

La hiperlipidemia es la principal causa de ateroesclerosis y ésta la principal etiología de la cardiopatía isquémica. Las estatinas son el recurso más utilizado para la reducción de las concentraciones sanguíneas de lípidos, en especial de lipoproteínas de baja densidad (LDL). Actualmente se ha incorporado otro recurso farmacológico formado por un grupo de fármacos, entre los que figuran la ezetimiba, que inhiben de manera preferencial la absorción intestinal de colesterol. Por esta razón, la administración conjunta de estatinas y ezetimiba adquiere un carácter lógico en la prevención de la cardiopatía isquémica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Assman G, Cullen P, Jossa F, Lewis B, Mancini M: Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide review. International Task force for the Prevention of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 1999; 19: 1819-1824.

  2. British Heart Foundation Statistics Database. Coronary heart disease statistics. Compiled by: British Heart Foundation Health Promotion Research Group. Disponible en: http://www.dphpc.ox.ac.uk/bhfhprg/stats/2000/2002/deyfactsindex.html

  3. Mahley RW, Bersot TP: Drug therapy for hypercholesterolemia and dyslipidemia. En: Hardman JG, Limbrid LE, eds. Goodman and Gilman The Pharmacologic Basis of Therapeutics. 10th ed. New York, NY: Mc Graw-Hill; 2001: 971-1002.

  4. Mahley RW, Weisgraber KH, Farese RV Jr: Disorders of lipid metabolism. En: Wilson JD, Foster DW, Kronenberg, HM, Larsen PR. Eds Williams Textbook of Endocrinology. 9th eds. Philadephia, Pa: WB Saunders Co; 1998: 1099-1153.

  5. Wilson PW, D Agostino RB, Levy D, Belanger AM, Silbershatz H, Kanmmel WP: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.

  6. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 larte cohorts of younger men to long term coronary, cardiovascular, and all cause mortality and to longevity. JAMA 2000; 284: 311-318.

  7. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I: reduction in incidence of coronary heart disease. JAMA 1984: 251: 351-364.

  8. Wood D, De Backer G, Faergoman O, Graham I, Mancia G, Pyörälä K: For the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice: recommendations of the Secod Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.

  9. Assmann G. Schulte H, Cullen P: New and classical risk factors –The Münter Heart Study (PROCAM). Eur J Med Res 1997; 2: 237-242.

  10. Kastelein J, van Dam MJ: A new role for combination therapy in lipid management. Bri J Cardiol 2001; 8: 639-653.

  11. Crouch MA: Effective use of statins to prevent coronary heart disease. Am Fam Physician 2001; 63: 309-320.

  12. Sueta CA, Chowdhury M. Bocuzzi SJ, et al: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-1307.

  13. Bays H: Ezetimibe. Expert Opin Investig Drugs 2002; 11: 1587-1604.

  14. Knopp RH, Gitter H, Truitt T, et al: for the Ezetimibe Study Group. Effects of Ezetimibe, a New Cholesterol Absorption Inhibitor, on Plasma Lipids in Patients With Primary Hypercholesterolemia. Eur Heart J 2003; 24: 729-741.




2020     |     www.medigraphic.com